v3.20.4
Segment and Geographic Area Information - Disaggregation of Revenue (Details) - USD ($)
$ in Millions
3 Months Ended 12 Months Ended
Dec. 31, 2020
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Disaggregation of Revenue        
Net revenues   $ 45,804 $ 33,266 $ 32,753
Total net revenues $ 13,858 45,804 33,266 32,753
United States        
Disaggregation of Revenue        
Net revenues   34,879 23,907 21,524
All other        
Disaggregation of Revenue        
Net revenues   2,923 2,068 2,408
Immunology | Humira        
Disaggregation of Revenue        
Net revenues   19,832 19,169 19,936
Immunology | Humira | United States        
Disaggregation of Revenue        
Net revenues   16,112 14,864 13,685
Immunology | Humira | International        
Disaggregation of Revenue        
Net revenues   3,720 4,305 6,251
Immunology | Skyrizi        
Disaggregation of Revenue        
Net revenues   1,590 355 0
Immunology | Skyrizi | United States        
Disaggregation of Revenue        
Net revenues   1,385 311 0
Immunology | Skyrizi | International        
Disaggregation of Revenue        
Net revenues   205 44 0
Immunology | Rinvoq        
Disaggregation of Revenue        
Net revenues   731 47 0
Immunology | Rinvoq | United States        
Disaggregation of Revenue        
Net revenues   653 47 0
Immunology | Rinvoq | International        
Disaggregation of Revenue        
Net revenues   78 0 0
Hematologic Oncology | Imbruvica        
Disaggregation of Revenue        
Net revenues   5,314 4,674 3,590
Hematologic Oncology | Imbruvica | United States        
Disaggregation of Revenue        
Net revenues   4,305 3,830 2,968
Hematologic Oncology | Imbruvica | International        
Disaggregation of Revenue        
Collaboration revenues   1,009 844 622
Hematologic Oncology | Venclexta        
Disaggregation of Revenue        
Net revenues   1,337 792 344
Hematologic Oncology | Venclexta | United States        
Disaggregation of Revenue        
Net revenues   804 521 247
Hematologic Oncology | Venclexta | International        
Disaggregation of Revenue        
Net revenues   533 271 97
Aesthetics | Botox Cosmetic        
Disaggregation of Revenue        
Net revenues [1]   1,112 0 0
Aesthetics | Botox Cosmetic | United States        
Disaggregation of Revenue        
Net revenues [1]   687 0 0
Aesthetics | Botox Cosmetic | International        
Disaggregation of Revenue        
Net revenues [1]   425 0 0
Aesthetics | Juvederm Collection        
Disaggregation of Revenue        
Net revenues [1]   718 0 0
Aesthetics | Juvederm Collection | United States        
Disaggregation of Revenue        
Net revenues [1]   318 0 0
Aesthetics | Juvederm Collection | International        
Disaggregation of Revenue        
Net revenues [1]   400 0 0
Aesthetics | Other Aesthetics        
Disaggregation of Revenue        
Net revenues [1]   760 0 0
Aesthetics | Other Aesthetics | United States        
Disaggregation of Revenue        
Net revenues [1]   666 0 0
Aesthetics | Other Aesthetics | International        
Disaggregation of Revenue        
Net revenues   94 [1] 0 [1] 0
Neuroscience | Botox Therapeutic        
Disaggregation of Revenue        
Net revenues [1]   1,387 0 0
Neuroscience | Botox Therapeutic | United States        
Disaggregation of Revenue        
Net revenues [1]   1,155 0 0
Neuroscience | Botox Therapeutic | International        
Disaggregation of Revenue        
Net revenues [1]   232 0 0
Neuroscience | Vraylar | United States        
Disaggregation of Revenue        
Net revenues [1]   951 0 0
Neuroscience | Duodopa        
Disaggregation of Revenue        
Net revenues   494 461 430
Neuroscience | Duodopa | United States        
Disaggregation of Revenue        
Net revenues   103 97 80
Neuroscience | Duodopa | International        
Disaggregation of Revenue        
Net revenues   391 364 350
Neuroscience | Ubrelvy | United States        
Disaggregation of Revenue        
Net revenues [1]   125 0 0
Neuroscience | Other Neuroscience        
Disaggregation of Revenue        
Net revenues [1]   539 0 0
Neuroscience | Other Neuroscience | United States        
Disaggregation of Revenue        
Net revenues [1]   528 0 0
Neuroscience | Other Neuroscience | International        
Disaggregation of Revenue        
Net revenues [1]   11 0 0
Eye Care | Lumigan/Ganfort        
Disaggregation of Revenue        
Net revenues [1]   378 0 0
Eye Care | Lumigan/Ganfort | United States        
Disaggregation of Revenue        
Net revenues [1]   165 0 0
Eye Care | Lumigan/Ganfort | International        
Disaggregation of Revenue        
Net revenues [1]   213 0 0
Eye Care | Alphagan/Combigan        
Disaggregation of Revenue        
Net revenues [1]   326 0 0
Eye Care | Alphagan/Combigan | United States        
Disaggregation of Revenue        
Net revenues [1]   223 0 0
Eye Care | Alphagan/Combigan | International        
Disaggregation of Revenue        
Net revenues [1]   103 0 0
Eye Care | Restasis        
Disaggregation of Revenue        
Net revenues [1]   787 0 0
Eye Care | Restasis | United States        
Disaggregation of Revenue        
Net revenues [1]   755 0 0
Eye Care | Restasis | International        
Disaggregation of Revenue        
Net revenues [1]   32 0 0
Eye Care | Other Eye Care        
Disaggregation of Revenue        
Net revenues [1]   693 0 0
Eye Care | Other Eye Care | United States        
Disaggregation of Revenue        
Net revenues [1]   305 0 0
Eye Care | Other Eye Care | International        
Disaggregation of Revenue        
Net revenues [1]   388 0 0
Women's Health | Lo Loestrin        
Disaggregation of Revenue        
Net revenues [1]   356 0 0
Women's Health | Lo Loestrin | United States        
Disaggregation of Revenue        
Net revenues [1]   346 0 0
Women's Health | Lo Loestrin | International        
Disaggregation of Revenue        
Net revenues [1]   10 0 0
Women's Health | Orilissa/Oriahnn        
Disaggregation of Revenue        
Net revenues   125 93 11
Women's Health | Orilissa/Oriahnn | United States        
Disaggregation of Revenue        
Net revenues   121 91 11
Women's Health | Orilissa/Oriahnn | International        
Disaggregation of Revenue        
Net revenues   4 2 0
Women's Health | Other Women's Health        
Disaggregation of Revenue        
Net revenues [1]   192 0 0
Women's Health | Other Women's Health | United States        
Disaggregation of Revenue        
Net revenues [1]   181 0 0
Women's Health | Other Women's Health | International        
Disaggregation of Revenue        
Net revenues [1]   11 0 0
Other Key Products | Mavyret        
Disaggregation of Revenue        
Net revenues   1,830 2,893 3,438
Other Key Products | Mavyret | United States        
Disaggregation of Revenue        
Net revenues   785 1,473 1,614
Other Key Products | Mavyret | International        
Disaggregation of Revenue        
Net revenues   1,045 1,420 1,824
Other Key Products | Creon | United States        
Disaggregation of Revenue        
Net revenues   1,114 1,041 928
Other Key Products | Lupron        
Disaggregation of Revenue        
Net revenues   752 887 892
Other Key Products | Lupron | United States        
Disaggregation of Revenue        
Net revenues   600 720 726
Other Key Products | Lupron | International        
Disaggregation of Revenue        
Net revenues   152 167 166
Other Key Products | Linzess/Constella        
Disaggregation of Revenue        
Net revenues [1]   667 0 0
Other Key Products | Linzess/Constella | United States        
Disaggregation of Revenue        
Net revenues [1]   649 0 0
Other Key Products | Linzess/Constella | International        
Disaggregation of Revenue        
Net revenues [1]   18 0 0
Other Key Products | Synthroid | United States        
Disaggregation of Revenue        
Net revenues   $ 771 $ 786 $ 776
[1] Net revenues include Allergan product revenues from the date of the acquisition, May 8, 2020, through December 31, 2020.